Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial

Takeda’s gut-selective biologic vedolizumab pushes ahead of other biologics in the race to make its mark in ulcerative colitis, a therapeutic sector targeted by numerous new investigational therapies.  

Heads
Blinded double-dummy head-to-head studies may be key to driving change in the IBD marketplace • Source: Shutterstock

Preliminary clinical data showing Takeda Pharmaceutical Co. Ltd.’s gut-selective biologic, vedolizumab (Entyvio), was superior to AbbVie Inc.’s anti-TNF biologic Humira (adalimumab) in achieving clinical remissions in patients with moderate-to-severe active ulcerative colitis could have important implications for clinical practice, and also commercially for the therapeutic sector.

The VARSITY study is thought to be one of the first head-to-head blinded comparisons of two biologics in inflammatory bowel...

More from Alimentary/Metabolic

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.